Hikal (HIKAL) Share Price Falls 8.34%: Hikal Share Price Today, Valuation and Peer View

Published:   24 September 2026 at 1:49:12 PM IST

Hikal Share Price opened the session weaker and ended at Rs 213.35, down 8.34% from the previous close, with market capitalisation at Rs 2,809.41 crore. The move places Hikal in focus for Hikal Share Price Today searches, Hikal Stock News and Hikal Share Price Fall queries because the fall came in a single session and changed the day’s price setup meaningfully. The supplied data confirms the share price decline, but it does not establish a company-specific catalyst. In that sense, the event is best read as a verified price action update rather than a reason-led news break. For readers tracking Hikal Share Price Live on Univest, the key question is how the day’s move compares with its valuation, profitability metrics and healthcare peer group.

The stock ended below the prior close of Rs 232.75 after opening at Rs 232.30, touching an intraday high of Rs 233.05 and a low of Rs 212.90. Turnover stood at Rs 1.72 crore. Those figures frame the day’s Hikal Share Price Today movement and provide the factual basis for Hikal Stock News coverage, without adding any unsupported explanation.

Hikal (HIKAL) Share Price Today: Price Action Analysis

Metric	Value
Current Price	Rs 213.35
Previous Close	Rs 232.75
Today's Move	-Rs 19.40 (-8.34%)
Open	Rs 232.3
High	Rs 233.05
Low	Rs 212.9
Turnover	Rs 1.72 crore
Market Capitalisation	Rs 2,809.41 crore
Market Cap Category	Small Cap

Hikal Share Price Today shows a clear single-day decline from Rs 232.75 to Rs 213.35, a fall of Rs 19.40 or 8.34%. The session opened at Rs 232.30, which was very close to the previous close, and the stock later moved through a high of Rs 233.05 before settling near the day’s low of Rs 212.90. That range shows a session in which the closing price ended near the lower end of the day’s trade. The market capitalisation of Rs 2,809.41 crore places Hikal in the supplied Small Cap category, which is a factual company-size descriptor rather than a comment on quality or behaviour. Turnover came in at Rs 1.72 crore, and that exact figure should be read only as the day’s traded value. On a pure price basis, the session turned Hikal Share Price Fall into the main stock-market headline for the name today. For the next layer of analysis, the important question is how this move compares with the stock’s fundamentals, sector benchmarks and peer set.

Hikal (HIKAL) Fundamental Analysis

Metric	Value
Market Capitalisation	Rs 2,809.41 crore
P/B Ratio	2.41x
ROE	-3.97%
ROCE	-0.83%
EPS	Rs -2.74
Book Value Per Share	Rs 96.62
Dividend Yield	0.26%

Hikal Share Price today can also be viewed through its fundamentals. The company’s market capitalisation is Rs 2,809.41 crore and its price-to-book ratio is 2.41, which places the stock below several premium-rated healthcare peers in the supplied set. Book value stands at Rs 96.62 per share, while EPS is Rs -2.74, indicating a loss at the per-share level in the latest supplied data. ROE is -3.97% and ROCE is -0.83%, both negative and therefore below the positive profitability levels shown by most peers in the benchmark set. Dividend yield is 0.26%, which is a factual historical/current yield measure and should not be read as a forecast. These numbers make the Hikal Share Price Fall more meaningful for Hikal Stock Analysis because the session happened against a backdrop of weak reported profitability metrics, even though the supplied data does not define a catalyst. For Hikal Fundamental Analysis searches, the main takeaway is that the day’s decline occurred with a valuation profile that is not stretched on P/B, but the earnings and return ratios remain negative. That balance is useful context for readers following Hikal Share Price News and Hikal Financial Results coverage on Univest.

Sector and Industry Context

Metric	Value
Sector	Healthcare
Industry	Pharmaceuticals & Drugs
Benchmark Scope	same industry
Benchmark Median P/E	31.9x
Benchmark Average P/E	50.01x
Benchmark P/E Range	3.48x to 762.66x
Company P/B Ratio	2.41x
Benchmark Median P/B	3x
Benchmark Average P/B	4.38x
Company ROE	-3.97%
Benchmark Median ROE	11.7%
Benchmark Average ROE	10.65%
Company ROCE	-0.83%
Benchmark Median ROCE	13.46%
Benchmark Average ROCE	13.26%
Company Market Capitalisation	Rs 2,809.41 crore
Benchmark Median Market Cap	Rs 761.61 crore
Benchmark Average Market Cap	Rs 14,299.75 crore

Hikal operates in Healthcare, within the Pharmaceuticals & Drugs industry. The supplied benchmark scope covers the same industry and includes 200 companies, giving a broad reference point for Hikal Share Price Today and sector comparison. Hikal’s valuation and return ratios can be set against that pool in a factual way.41 is below the sector median P/B of 3 and below the sector average P/B of 4.38 across 199 companies. Its ROE of -3.97% is below the sector median ROE of 11.7% and the sector average ROE of 10.65 across 200 companies. ROCE at -0.83% is also below the sector median ROCE of 13.46% and the sector average ROCE of 13.26 across 200 companies. In market-cap terms, Hikal’s Rs 2,809.41 crore is above the sector median of Rs 761.61 crore and far below the sector average of Rs 14,299.75 crore across 200 companies. For sector-aware readers following Hikal Share Price News, that combination means the stock sits as a smaller healthcare name with a valuation below the broader industry median on P/B, while returns remain negative.

Peer Comparison

Company	Symbol	Market Cap (Cr)	P/E	P/B	ROE (%)	ROCE (%)
Sun Pharmaceutical Industries	SUNPHARMA	4,42,437.37	37	5.17	14.85	19.11
Divi's Laboratories	DIVISLAB	2,48,053.84	87.1	14.42	16.19	21.51
Torrent Pharmaceuticals	TORNTPHARM	1,89,841.6	86.85	21.1	26.76	19.27
Zydus Lifesciences	ZYDUSLIFE	1,15,810.19	25.85	4.33	19.69	21.39
Cipla	CIPLA	1,11,565.25	33.08	3.17	11.83	16

The supplied peer set for Hikal Share Price analysis includes Sun Pharmaceutical Industries, Divi’s Laboratories, Torrent Pharmaceuticals, Zydus Lifesciences and Cipla Hikal’s market cap of Rs 2,809.41 crore is well below all five listed peers in the supplied comparison, which places it at the smaller end of the group by size. On valuation, Hikal’s P/B of 2.41 is below Sun Pharma at 5.17, Divi’s at 14.42, Torrent Pharma at 21.1, Zydus Lifesciences at 4.33 and Cipla at 3.17. On returns, Hikal’s ROE of -3.97% and ROCE of -0.83% are below every supplied peer, all of which show positive ROE and ROCE values. The peer data therefore frames Hikal Share Price Today as a stock trading on a lower P/B than the selected group, but with weaker reported return metrics. That is the relevant comparison for Hikal Stock News readers who want a clean, number-led view rather than a narrative guess.

Why Investors Are Watching Hikal

• Hikal Share Price fell 8.34% to Rs 213.35 today, with the stock closing below the previous close of Rs 232.75.
• The intraday range ran from Rs 233.05 to Rs 212.90, which defines the day’s Hikal Share Price Today move.
• Market capitalisation stands at Rs 2,809.41 crore, and the company is tagged as Small Cap in the supplied data.
• P/B is 2.41, EPS is Rs -2.74, ROE is -3.97% and ROCE is -0.83% in the latest data.
• The peer set shows higher P/B and positive return ratios for Sun Pharma, Divi’s, Torrent Pharma, Zydus Lifesciences and Cipla.

About Hikal

Hikal operates in Healthcare and the Pharmaceuticals & Drugs industry. The supplied data places the company within a peer group that includes large listed healthcare names such as Sun Pharmaceutical Industries, Divi’s Laboratories, Torrent Pharmaceuticals, Zydus Lifesciences and Cipla For Hikal Share Price readers, this sector and industry placement is important because it defines the benchmark set used by the market for valuation and return comparison. The company’s current market cap, book value, EPS, ROE, ROCE and dividend yield form the core of the latest Hikal Stock News picture, while today’s share price decline adds a fresh event to monitor on Univest.

Track Hikal Share Price on Univest

Use Hikal (HIKAL) live share-price page,Univest top decliners screener,Univest market blogs to review live stock data, top decliners and related market analysis.

Readers tracking Hikal Share Price on Univest can follow live price updates, market cap, key valuation ratios, shareholding pattern, 52-week levels and company insights in one place. Univest also presents stock analysis, fundamental ratios and sector context for Hikal Share Price Today, helping users monitor the stock’s latest news flow and daily price action.

Frequently Asked Questions

Why did Hikal Share Price fall today?

Ans.  Hikal Share Price fell 8.34% to Rs 213.35 today. The supplied data confirms the price event, but it does not establish a company-specific catalyst behind the move. The previous close was Rs 232.75.

What is Hikal Share Price today?

Ans.  Hikal Share Price today is Rs 213.35. That compares with the previous close of Rs 232.75, showing a day decline of Rs 19.40 in the latest session. The previous close was Rs 232.75.

What is Hikal market capitalisation?

Ans.  Hikal’s market capitalisation is Rs 2,809.41 crore. The supplied data places it in the Small Cap category, which is a size descriptor and not a comment on quality or outlook.

What do Hikal fundamentals show?

Ans.  Hikal shows a P/B of 2.41, EPS of Rs -2.74, ROE of -3.97%, ROCE of -0.83% and dividend yield of 0.26%. These figures provide context for the latest Hikal Share Price move.

How does Hikal compare with sector benchmarks?

Ans.  Hikal’s P/B of 2.41 is below the sector median of 3 and average of 4.38. Its ROE and ROCE are also below the sector median and average in the supplied healthcare benchmark set.

How does Hikal compare with peers?

Ans.  In the supplied peer list, Hikal has a smaller market cap and lower return ratios than Sun Pharma, Divi’s, Torrent Pharma, Zydus Lifesciences and Cipla. Its P/B is also below each of those peers.

What should investors monitor next in Hikal Share Price?

Ans.  Investors can monitor the next Hikal Share Price update alongside market cap, book value, EPS, ROE, ROCE and peer comparison. The current data set confirms the decline but not the cause.